sulfonylureas
- Generic Name
- sulfonylureas
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Dipeptidyl Peptidase-4 Inhibitor (DPP-4)Drug: Glucagon-Like Peptide-1 Agonist (GLP-1)
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 25358
- Registration Number
- NCT03249506
- Locations
- πΊπΈ
Health ResearchTx, LLC, Trevose, Pennsylvania, United States
Incretin-based Drugs and Acute Pancreatitis
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: InsulinsDrug: BiguanidesDrug: DPP-4 inhibitorsDrug: GLP-1 analogsDrug: ThiazolidinedionesDrug: Meglitinides
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
- Target Recruit Count
- 1417914
- Registration Number
- NCT02476760
- Locations
- π¨π¦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
Incretin-based Drugs and Pancreatic Cancer
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: DPP-4 inhibitorsDrug: BiguanidesDrug: GLP-1 analogsDrug: ThiazolidinedionesDrug: Meglitinides
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
- Target Recruit Count
- 886172
- Registration Number
- NCT02475499
- Locations
- π¨π¦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
Incretin-based Drugs and the Risk of Heart Failure
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: InsulinsDrug: BiguanidesDrug: DPP-4 inhibitorsDrug: GLP-1 analogsDrug: ThiazolidinedionesDrug: Meglitinides
- First Posted Date
- 2015-05-28
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
- Target Recruit Count
- 1499650
- Registration Number
- NCT02456428
- Locations
- π¨π¦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 774
- Registration Number
- NCT01648582
- Locations
- π·πΊ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sankt-Petersburg, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath